Streetbeat News

Revenues

NEO

NeoGenomics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 4:19 pm

AGCO

AGCO Corporation (NYSE:AGCO) shares are trading lower after reporting worse-than-expected Q2 financial results and lowering its FY24 guidance. The company missed analyst expectations for both earnings and sales, and announced significant production cuts and a sale of its Grain & Protein business.

Portfolio Pulse from Nabaparna Bhattacharya

July 30, 2024 | 4:14 pm

CCJ

EGRAF

RIO

Uranium prices have surged to 16-year highs due to supply uncertainties and rising demand, particularly for AI data centers. Cameco (NYSE:CCJ) is locking in higher contract prices, while Energy Resources of Australia (OTCPK:EGRAF) and Rio Tinto (NYSE:RIO) face challenges due to Australia's mining ban at the Jabiluka site.

Portfolio Pulse from Stjepan Kalinic

July 30, 2024 | 4:13 pm

QQQ

SPY

August is historically a weak month for stock market returns, with major indices like the S&P 500, Nasdaq 100, and NYSE Composite showing low to negative average returns. The SPDR S&P 500 ETF (SPY) and Invesco QQQ Trust (QQQ) reflect these trends. Investors should consider seasonality as one of many factors in their trading decisions.

Portfolio Pulse from Cory Mitchell

July 30, 2024 | 4:13 pm

ZBRA

Zebra Technologies Corp (NASDAQ:ZBRA) reported better-than-expected Q2 2024 results, with net sales of $1.22 billion and adjusted EPS of $3.18, both beating analyst estimates. The EVM segment showed strong growth, while the AIT segment saw a decline. The company improved its gross margin but faced higher operating expenses. Zebra expects significant sales growth in Q3 and fiscal 2024, raising its guidance.

Portfolio Pulse from Anusuya Lahiri

July 30, 2024 | 4:10 pm

BMY

MRK

MYNZ

PFE

Pfizer has recorded its first sales growth in the post-COVID era, driven by cancer and heart drugs. Smaller players like Mainz Biomed are also making strides in oncology. Pfizer's Q2 revenue grew 3% YoY to $13.28 billion, with significant contributions from cancer therapies and heart disease drugs. Merck also exceeded estimates, driven by its cancer drug Keytruda. Pfizer raised its full-year outlook, expecting earnings per share between $2.45 and $2.65.

Portfolio Pulse from Upwallstreet

July 30, 2024 | 4:09 pm

CMG

MCD

SBUX

McDonald's reported a challenging second quarter, missing Wall Street estimates and experiencing its first sales drop since 2020. The company is losing low-income consumers and facing a competitive environment. Chipotle and Starbucks are also mentioned as facing similar challenges, with Chipotle expected to report earnings soon and Starbucks likely to post a drop in earnings.

Portfolio Pulse from Upwallstreet

July 30, 2024 | 4:03 pm

LRLCY

L'Oreal reported a 2.4% decline in Q2 North Asia comparable sales, missing the estimated decline of 0.62%.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 4:03 pm

BRX

Four analysts have recently evaluated Brixmor Property Group (NYSE:BRX), with mixed ratings ranging from 'Hold' to 'Neutral'. The average 12-month price target has decreased by 1.52% to $24.62. The company's financial performance shows strong net margins and ROE, but its revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

July 30, 2024 | 4:01 pm

ARQT

Analysts have provided diverse evaluations of Arcutis Biotherapeutics (NASDAQ:ARQT) over the past three months, with all four analysts maintaining a bullish outlook. The average 12-month price target has increased to $18.00 from $17.25. The company's lead product, ZORYVE roflumilast cream, has shown positive results in Phase 3 clinical trials for plaque psoriasis. Despite impressive revenue growth, the company faces challenges with its net margin, ROE, and debt management.

Portfolio Pulse from Benzinga Insights

July 30, 2024 | 4:00 pm